Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

The Trust Test

- PMLiVE

CHMP recommends use of Moderna’s Omicron BA.1 booster in children in the EU

The company is also evaluating the use of the vaccine in children aged from six months

- PMLiVE

MHRA set to receive nearly £1m from BEIS’ Regulator’s Pioneer Fund

Funding will aid three projects aiming to harness digital, data and scientific regulatory innovation

- PMLiVE

WHO joins calls for equitable access to healthcare products ahead of future pandemics

The WHO, WIPO and WTO gathered at the Joint Technical Symposium on 16 December

- PMLiVE

BioXcel Therapeutics doses first patient in phase 3 Alzheimer’s-associated agitation trial

Around 100 million agitation episodes are reported in the US each year in Alzheimer’s patients

- PMLiVE

Focusing on ‘treating the patient, not the disease’ can transform the outlook for cardiovascular disease

Sharpening the focus to ‘treating the patient, not the disease’ can lead to a paradigm shift in outcomes

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced gastric cancer

Approximately 136,000 cases of gastric cancer are diagnosed annually in Europe

- PMLiVE

Sanofi/ Regeneron’s Dupixent recommended by CHMP to treat eosinophilic oesophagitis

Patients in a phase 3 trial experienced improvements in their ability to swallow after four weeks

- PMLiVE

New research shows potential to treat kidney disease with common medicines

Acute kidney injuries cause around 20% of all emergency hospital admissions in the UK

- PMLiVE

Retrospective prospective

Looking back at what we learned in 2022 and what the new year may bring

healthcare meeting

UNDERSTANDING THE ROLE OF PLACE WITHIN THE NEW NHS: FIVE THINGS INDUSTRY NEEDS TO KNOW

Operating a level below system, “place” is an increasingly important unit of NHS organisation, yet it remains an evolving concept that is not always well-understood among industry practitioners. In this...

Wilmington Healthcare

- PMLiVE

Novartis receives EC approval for Pluvicto to treat adult cancer patients

Patients receiving Pluvicto plus best standard of care had a 38% reduction in the risk of death

- PMLiVE

UK Government commit £50m to motor neurone disease research

The pledged funding is being placed into the hands of researchers ‘as quickly as possible’

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links